Compare Charles Schwab Corporation Common Stock (SCHW) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles Schwab Corporation Common Stock vs Summit Therapeutics Inc — how do they compare? Charles Schwab Corporation Common Stock trades at $96.7 (market cap $167.52B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 12.2× Summit Therapeutics Inc's market cap, and Charles Schwab Corporation Common Stock pays a 1.32% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles Schwab Corporation Common Stock for 85 Days and Summit Therapeutics Inc for 16 Days on average.
| SCHW | SMMT | |
|---|---|---|
Market Cap | $167.52B | $13.71B |
Volume | 6,554,126 | 6,173,057 |
Sector | Financials | Health |
52-Week High | $113.65 | $26.38 |
52-Week Low | $85.35 | $12.43 |
Typical Hold Time | 85 Days | 16 Days |
Enterprise Value | $153.97B | $13.04B |
Dividend Yield | 1.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles Schwab (SCHW) trades at $96.87, up 1.35% on the day, with a bearish technical signal but strong fundamentals. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $1.62 exceeding the $1.56 estimate. Revenue for 2025 reached $23.92 billion, driving a net income margin of 38.79%. Analyst consensus is bullish with a $120.33 price target, and recent news highlights growth in client assets and AI integration for advisors.
The outlook remains positive given strong profitability and market share gains, though technical weakness and interest rate sensitivity pose near-term risks. Earnings momentum and strategic initiatives like the Texas Stock Exchange listing support upside potential, but investors should monitor competitive pressures and macroeconomic volatility.
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.
The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
